KURA ONCOLOGY DL-,0001 WKN: A143UH ISIN: US50127T1097 Kürzel: KUR Forum: Aktien Thema: Hauptdiskussion

Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results https://www.globenewswire.com/news-release/2021/02/24/2181292/0/en/Kura-Oncology-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html -  Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations – – KO-539 continues to demonstrate a wide therapeutic window in dose escalation; protocol amendment to include genetically enriched Phase 1 expansion cohorts – – Tipifarnib receives Breakthrough Therapy Designation from FDA – – $633.3 million in cash, cash equivalents and investments provide runway into 2024 – Management to host webcast and conference call today at 8:00 a.m. ET –    ....

Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma http://www.globenewswire.com/news-release/2021/02/24/2181242/0/en/Kura-Oncology-Receives-FDA-Breakthrough-Therapy-Designation-for-Tipifarnib-in-Head-and-Neck-Squamous-Cell-Carcinoma.html ...today announced that its investigational drug, tipifarnib, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma (HNSCC) with variant allele frequency ≥ 20% after disease progression on platinum-based chemotherapy. Tipifarnib is currently being evaluated in an ongoing registration-directed clinical trial (AIM-HN) in this indication of high unmet need.  ...

Kura teams up with Illumina for a companion diagnostic for lead therapy https://seekingalpha.com/news/3650072-kura-teams-up-illumina-for-companion-diagnostic-for-lead-therapy In a regulatory filing, Kura Oncology (NASDAQ:KURA) announces that on January 04, it entered into a collaboration agreement, with Illumina (NASDAQ:ILMN) for a companion diagnostic test for use with the company’s lead product candidate, tipifarnib. The agreement tided to a project schedule will require Illumina to develop and commercialize an assay as a companion diagnostic test for use with tipifarnib to identify head and neck squamous cell carcinoma (‘HNSCC”) patients with an HRAS mutation. The collaboration covers the United States, the United Kingdom, major European markets, and other countries as mutually agreed by the two parties. Currently, Kura is advancing a global, multi-center, open-label, non-comparative registration-directed clinical trial of tipifarnib in HRAS mutant HNSCC.

Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares https://www.globenewswire.com/news-release/2020/12/11/2144046/0/en/Kura-Oncology-Announces-Closing-of-Public-Offering-and-Full-Exercise-of-Option-to-Purchase-Additional-Shares.html

https://seekingalpha.com/article/4394095-kura-oncology-advanced-precision-medicine-opportunity-excites-not-without-risks

Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock https://www.globenewswire.com/news-release/2020/12/09/2141845/0/en/Kura-Oncology-Announces-Pricing-of-300-Million-Public-Offering-of-Common-Stock.html ...at a price to the public of $37.00 per share. 

Kura Oncology Announces Commencement of Public Offering of Common Stock https://www.globenewswire.com/news-release/2020/12/07/2140893/0/en/Kura-Oncology-Announces-Commencement-of-Public-Offering-of-Common-Stock.html

https://seekingalpha.com/news/3642222-kura-oncology-sized-up-favorably-for-long-term-after-ash-presentation

https://seekingalpha.com/news/3642092-kura-oncology-jumps-16-after-announcing-first-in-human-data-for-aml-candidate Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate

🍀

Kura Oncology Reports Third Quarter 2020 Financial Results https://www.globenewswire.com/news-release/2020/11/05/2120945/0/en/Kura-Oncology-Reports-Third-Quarter-2020-Financial-Results.html – Preliminary data from first-in-human trial of menin inhibitor KO-539 accepted for oral presentation at ASH – – Encouraging safety, tolerability and activity with KO-539 highlighted in ASH abstract – – Preclinical data support expansion opportunity for tipifarnib plus PI3Kα inhibitor in HRAS- and/or PI3K-dependent tumors – – $325.4 million in cash, cash equivalents and investments provide runway into 2023 – ...

https://www.globenewswire.com/news-release/2020/10/07/2104839/0/en/Kura-Oncology-Announces-Preliminary-Data-for-Menin-Inhibitor-KO-539-Accepted-for-Oral-Presentation-at-ASH.html Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH – First clinical data from the KOMET-001 study to be presented on December 5, 2020 –

.

👀

Phase 2 und solche Auswirkungen? Hätte auch gerne bei Array so sein können

KURA has positive topline results from a Phase 2 trial for its lead product candidate, tipifarnib, in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC).